<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31671">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01766518</url>
  </required_header>
  <id_info>
    <org_study_id>m307LTP09D</org_study_id>
    <nct_id>NCT01766518</nct_id>
  </id_info>
  <brief_title>The Study to Evaluate Efficacy and Safety of MY-REPT Capsule in Primary, Liver Transplantation Recipients (MYLT1)</brief_title>
  <official_title>Open Label, Multicenter, Non-comparative Study to Evaluate the Efficacy and Safety of MY-REPT Capsule in Primary, Liver Transplantation Recipients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <authority>South Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and safety of MY-REPT capsule in primary, liver transplantation recipients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open label, Multicenter, Non-comparative Study to evaluate the efficacy and safety of
      MY-REPT capsule in primary, liver transplantation
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Rate of acute rejection</measure>
    <time_frame>up to 26weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rate acute rejection by liver biopsy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency, Time, Severity of acute rejection</measure>
    <time_frame>up to 26 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft loss, Patient survival rate</measure>
    <time_frame>up to 26weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney function test by e-GFR(Glomerular filtration rate)</measure>
    <time_frame>up to 26weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire of gastrointestinal symptom assessment</measure>
    <time_frame>screening visit, closing visit</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire of gastrointestinal quality of life index</measure>
    <time_frame>screening visit, closing visit</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Rate of adverse event</measure>
    <time_frame>up to 26 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory test</measure>
    <time_frame>up to 26weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Physical exam, pulse rate et.</measure>
    <time_frame>up to 26weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Evidence of Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>MY-REPT capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MY-REPT capsule: Mycophenolate mofetil, 250mg/cap, orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>MY-REPT capsule 500~1500mg/day, per oral, capsules twice a day with Tacrolimus, Corticosteroids, Basiliximab post liver transplantation</description>
    <arm_group_label>MY-REPT capsule</arm_group_label>
    <other_name>MY-REPT capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with primary liver transplantation recipients

          -  Male and Female aged ≥19 and ≤65

          -  Patient with ABO blood type correspond with Donor's blood type

          -  Patient who agreement with written informed consent

          -  Patient who Women if had childbearing potential must have a negative serum or urine
             pregnancy test at the screening visit and agreement with contraception

        Exclusion Criteria:

          -  Patient with secondary liver transplantation(LT) recipient or other organ
             transplantation recipient in past or current

          -  Patient with multi-organ transplantation recipient

          -  Patient with dual-graft transplantation recipient

          -  Patient who used body artificial liver before LT

          -  Cr level &gt;2.0mg/dL in screening

          -  WBC &lt;2,000/mm3 or ANC &lt;900/mm3 or PLT &lt;30,000/mm3 in screening

          -  Patient who experienced severe gastrointestinal disorder so investigator judge the
             man's participation impossible

          -  Patient who experienced severe infection (need to treatment)

          -  Patient or Donor with HIV positive

          -  Patient who need to treat with immunosuppressant or chemistry therapy

          -  Patient who had taken immunosuppressant within 30days before LT (except to take
             Corticosteroids and Tacrolimus due to protocol)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SungGyu Lee, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>SungGyu Lee, Ph.D</last_name>
    <phone>+82 2 3010 7182</phone>
    <email>sglee2@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan medical center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SungGyu Lee, Ph.D</last_name>
      <phone>+82 2 3010 7182</phone>
      <email>sglee2@amc.ac.kr</email>
    </contact>
    <investigator>
      <last_name>SungGyu Lee, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Seoul ST Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 6, 2013</lastchanged_date>
  <firstreceived_date>January 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>liver transplantation</keyword>
  <keyword>LT</keyword>
  <keyword>Mycophenolate mofetil</keyword>
  <keyword>MMF</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mycophenolate mofetil</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
